Table 1.

The compounds selected from the Drugbank database based on their binding affinity for the four vital targets in Covid-19.

3CLpro	PLpro	RdRp	Spike
Approved
Olaparib ($-$ 9.2)	Tadalafil ($-$ 9.2)	Lumacaftor ($-$ 9.9)	Dexamethasone metasulfobenzoate ($-$ 10.4)
Baloxavir marboxil ($-$ 8.9)	Metocurine($-$ 9.0)	Ergotamine ($-$ 9.4)	Nilotinib ($-$ 9.9)
Entrectinib, (− 8.7)	Lorlatinib ($-$ 9.0)	Natamycin($-$ 9.4)	Sonidegib ($-$ 9.8)
Dexamethasone metasulfobenzoate ($-$ 8.7)	Lumacaftor ($-$ 8.9)	Dihydroergotamine ($-$ 9.3)	Enasidenib ($-$ 9.8)
Tadalafil ($-$ 8.7)	Natamycin ($-$ 8.8)	Imatinib ($-$ 9.3)	Regorafenib, Lifitegrast, Capmatinib ($-$ 9.7)
Investigational
LY-2090314 ($-$ 10.3)	Zoliflodacin ($-$ 9.8)	Phthalocyanine ($-$ 10.6)	Lifirafenib ($-$ 10.7)
10-hydroxy camptothecin ($-$ 9.3)	JE-2147 ($-$ 9.7)	RU85053 ($-$ 9.9)	Resiniferatoxin ($-$ 10.6)
Tivantinib ($-$ 9.0)	Phthalocyanine ($-$ 9.6)	Laniquidar ($-$ 9.9)	JTK-853 ($-$ 10.6)
Lurtotecan ($-$ 9.0)	Quarfloxin ($-$ 9.5)	CD564 ($-$ 9.8)	Tegobuvir ($-$ 10.5)
Zk-806450 ($-$ 8.9)	CP-609754 ($-$ 9.5)	Golvatinib ($-$ 9.8)	PCO-371 ($-$ 10.5)

The binding affinities are given in kcal/mol.